You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RET positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 16, 2022

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Irvine, California
  • +3 more
Aug 30, 2021

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

Not yet recruiting
  • Thyroid Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 20, 2022

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

    Active, not recruiting
    Has Results
    • Solid Tumor
    • Medullary Thyroid Cancer
    • Guangzhou, Guangdong, China
    • +12 more
    May 9, 2022

    Refractory Solid Tumors Trial in Seoul (sunitinib)

    Completed
    • Refractory Solid Tumors
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Jun 13, 2022

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    Pralsetinib to Best Available Therapy in RET-Fusion Positive

    Enrolling by invitation
    • RET-fusion Non Small Cell Lung Cancer
    • +16 more
      • New York, New York
      • +2 more
      Aug 9, 2021

      NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +3 more
      • Scottsdale, Arizona
      • +84 more
      Oct 10, 2022

      Vandetanib in RET -/+ Metastatic Medullary Thyroid Cancer

      Completed
      • Symptomatic, Aggressive, Sporadic, Unresectable, Locally
      • Advanced/Metastatic Medullary Thyroid Cancer (MTC)
      • Vandetanib 300 mg
      • Belgium, Belgium
      • +7 more
      Oct 15, 2020

      NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Berazategui, Buenos Aires, Argentina
      • +195 more
      Jan 30, 2023

      RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

      Active, not recruiting
      • RET-altered Non Small Cell Lung Cancer
      • +39 more
      • pralsetinib (BLU-667)
      • Phoenix, Arizona
      • +65 more
      Nov 10, 2022

      Advanced Solid Tumor Trial in Los Angeles (EP0031)

      Recruiting
      • Advanced Solid Tumor
      • Los Angeles, California
      • +3 more
      Dec 1, 2022

      KIF5B-RET-Positive Adenocarcinoma of the Lung Trial in Worldwide (Lenvatinib)

      Completed
      Has Results
      • KIF5B-RET-Positive Adenocarcinoma of the Lung
      • Duarte, California
      • +22 more
      Jul 19, 2019

      Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)

      Recruiting
      • Medullary Thyroid Cancer
      • Birmingham, Alabama
      • +148 more
      Jan 18, 2023

      NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +2 more
      • Shanghai, Shanghai, China
      • +1 more
      Mar 17, 2022

      Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

      Recruiting
      • Malignant Thyroid Gland Neoplasm
      • +6 more
      • Quality-of-Life Assessment
      • +3 more
      • Ann Arbor, Michigan
      • +1 more
      Jan 24, 2023

      Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)

      Not yet recruiting
      • Breast Cancer
      • Singapore, Singapore
        Nationa University Hospital
      Jan 4, 2022

      Non Small Cell Lung Cancer Trial in Italy (Cabozantinib 20 MG, Cabozantinib 40 MG, Cabozantinib 60 MG)

      Recruiting
      • Non Small Cell Lung Cancer
      • Cabozantinib 20 MG
      • +2 more
      • Bologna, Italy
      • +10 more
      Oct 17, 2019

      ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,

      Terminated
      Has Results
      • ALK Fusion Protein Expression
      • +14 more
      • San Francisco, California
        University of California, San Francisco
      Jan 14, 2020

      Resistance-associated Mutations in Metastatic Lung Cancer

      Recruiting
      • Lung Cancer
      • Liquid biopsy
      • Monza, MB, Italy
        Fondazione IRCCS San Gerardo dei Tintori
      Oct 10, 2023

      Cervical/Supraclavicular Metastasis From Non-small-cell Lung

      Recruiting
      • Lung Cancer Metastatic
      • Needle or forceps biopsy of cervical and/or supraclavicular lymph nodes
      • Needle, forceps or surgical biopsy of any lesion other than cervical and/or supraclavicular lymph nodes
      • Roma, Italy
        Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      Jan 23, 2023

      Solid Tumor Trial in Shanghai (HS-10365)

      Recruiting
      • Solid Tumor
      • Shanghai, Shanghai, China
        Shanghai Chest Hospital
      Jan 24, 2022